Morgan Stanley started coverage on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a research note issued to investors on Thursday morning, MarketBeat reports. The brokerage issued an equal weight rating and a $155.00 target price on the specialty pharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on JAZZ. Cowen and Company reissued an outperform rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Piper Jaffray Companies reissued an overweight rating and issued a $182.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. BMO Capital Markets increased their price target on shares of Jazz Pharmaceuticals PLC from $192.00 to $196.00 and gave the stock an outperform rating in a report on Wednesday, June 7th. BidaskClub raised shares of Jazz Pharmaceuticals PLC from a sell rating to a hold rating in a report on Saturday, June 10th. Finally, J P Morgan Chase & Co reissued an overweight rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Monday, June 12th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eighteen have given a buy rating to the company. Jazz Pharmaceuticals PLC has a consensus rating of Buy and a consensus target price of $179.79.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 146.47 on Thursday. The company has a market capitalization of $8.80 billion, a price-to-earnings ratio of 22.56 and a beta of 1.05. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75. The firm has a 50-day moving average of $148.77 and a 200 day moving average of $151.49.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The firm had revenue of $394.39 million during the quarter, compared to analysts’ expectations of $410.83 million. During the same period in the previous year, the company posted $2.67 earnings per share. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. Analysts expect that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Research Coverage Started at Morgan Stanley” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-research-coverage-started-at-morgan-stanley/1619092.html.

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Paul L. Berns sold 662 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $142.37, for a total transaction of $94,248.94. Following the completion of the transaction, the director now owns 6,599 shares in the company, valued at approximately $939,499.63. The disclosure for this sale can be found here. Insiders sold 9,297 shares of company stock worth $1,429,417 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Toronto Dominion Bank grew its holdings in shares of Jazz Pharmaceuticals PLC by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after purchasing an additional 81 shares during the last quarter. US Bancorp DE grew its holdings in shares of Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 368 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after purchasing an additional 295 shares during the last quarter. World Asset Management Inc bought a new position in shares of Jazz Pharmaceuticals PLC in the first quarter worth approximately $205,000. Finally, Gargoyle Investment Advisor L.L.C. bought a new position in shares of Jazz Pharmaceuticals PLC in the second quarter worth approximately $206,000. Hedge funds and other institutional investors own 88.34% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.